Wiebe Ericka M, Stafford Alan R, Fredenburgh James C, Weitz Jeffrey I
Henderson Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada.
J Biol Chem. 2003 Sep 12;278(37):35767-74. doi: 10.1074/jbc.M304803200. Epub 2003 Jun 27.
Because of the homology between factor IXa and factor Xa (f.IXa and f.Xa, respectively), and the critical upstream position of f.IXa in the coagulation cascade, the contribution of the heparin-derived pentasaccharide to antithrombin-mediated inhibition of f.IXa was investigated. Pentasaccharide promotes inhibition of both f.IXa and f.Xa generated in recalcified plasma. This result demonstrates that antithrombin is the predominant inhibitor of f.IXa in plasma, and that the activity of antithrombin is promoted by pentasaccharide. Kinetic experiments reveal that pentasaccharide increases the rates of antithrombin-mediated inhibition of both f.IXa and f.Xa by 2 orders of magnitude. These findings indicate that pentasaccharide-induced conformational changes in antithrombin enhance its capacity to inhibit both f.IXa and f.Xa. In the presence of Ca2+, full-length heparin produces an additional approximately 10-fold increase in the rates of inhibition of both enzymes, consistent with a template role of heparin. Heparin binding to f.Xa was previously shown to be promoted in the presence of Ca2+. Binding studies with f.IXa reveal a 10-fold higher affinity for heparin in the presence of Ca2+ compared with its absence. Thus, Ca2+ promotes heparin-catalyzed inhibition of f.IXa and f.Xa by antithrombin by augmenting the template mechanism. These results indicate that heparin-mediated catalysis of f.IXa inhibition by antithrombin reflects both pentasaccharide-induced conformational changes and heparin-mediated bridging of antithrombin to f.IXa. Furthermore, our data suggest that the efficacy of pentasaccharide for prevention and treatment of thrombotic disorders may reflect its action at two sites in the coagulation system.
由于凝血因子IXa与凝血因子Xa(分别为f.IXa和f.Xa)之间存在同源性,且f.IXa在凝血级联反应中处于关键的上游位置,因此研究了肝素衍生的五糖对抗凝血酶介导的f.IXa抑制作用的贡献。五糖可促进对抗凝血酶介导的再钙化血浆中生成的f.IXa和f.Xa的抑制作用。这一结果表明,抗凝血酶是血浆中f.IXa的主要抑制剂,且五糖可促进抗凝血酶的活性。动力学实验表明,五糖可使抗凝血酶介导的f.IXa和f.Xa抑制速率提高2个数量级。这些发现表明,五糖诱导的抗凝血酶构象变化增强了其抑制f.IXa和f.Xa的能力。在Ca2+存在的情况下,全长肝素可使两种酶的抑制速率额外提高约10倍,这与肝素的模板作用一致。先前已证明,在Ca2+存在的情况下,肝素与f.Xa的结合会增强。对f.IXa的结合研究表明,与不存在Ca2+时相比,在Ca2+存在的情况下,肝素对f.IXa的亲和力高10倍。因此,Ca2+通过增强模板机制促进了肝素催化的抗凝血酶对f.IXa和f.Xa的抑制作用。这些结果表明,肝素介导的抗凝血酶对f.IXa的催化抑制作用既反映了五糖诱导的构象变化,也反映了肝素介导的抗凝血酶与f.IXa的桥连作用。此外,我们的数据表明,五糖预防和治疗血栓性疾病的疗效可能反映了其在凝血系统中两个位点的作用。